ClinicalTrials.gg
RecruitingNCT06879925QG-PASCUpdated Mar 17, 2025

Physiological and QoL Benefits of Qi-Gong in Post-acute Sequelae of Covid-19

An interventional study of QI-GONG and control in PASC Post Acute Sequelae of COVID 19, sponsored by POCHIWU. Recruiting at 2 sites in Taiwan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by POCHIWU · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan — 5 open to participants now, 5 under way, none of them phase 3. Post-Acute COVID-19 Syndrome · Taiwan.

Planned enrollment
5th of 11
80 · median 68
Started
2024
the only one that year
No phase
10 of 15
1 open now
Registered
12th of 15
by date
Lead sponsor
1 of 15
POCHIWU

Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 10 with no phase, and was the 12th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

5 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC).

Study Objectives:

To assess whether Qi-Gong improves physiological function in individuals with PASC.

To evaluate whether Qi-Gong enhances quality of life in individuals with PASC.

Study Design:

If a comparison group is included, researchers will compare Qi-Gong with standard care to assess its effectiveness.

Participant Involvement:

Practice Qi-Gong three times per week for three months. Record physiological data monthly.

03

Conditions studied

  • PASC Post Acute Sequelae of COVID 19
04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PASC
  • above 20 y/o

Exclusion criteria

Exclusion Criteria:

  • Those who cannot cooperate
  • Severe schizophrenia
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Qi-Gong Group

    Experimental Group :Qi-Gong(yijinjing)

    Behavioral: QI-GONG and control

  • No intervention
    routine care Group

    Control Group:routine care

Interventions

  • BehavioralQI-GONG and control

    QIGONG

06

What researchers measure

Primary outcomes

  1. Pulmonary Function Test (Forced vital capacity)

    FVC,over 80% is better

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Pulmonary Function Test (FEV1)

    FEV1,over 80% is better

    Time frame: From enrollment to the end of treatment at 12 weeks

  3. Pulmonary Function Test (FVCFEV1)

    FVCFEV1,over 80% is better

    Time frame: From enrollment to the end of treatment at 12 weeks

  4. Heart rate variability

    Low Frequency,40%-60%

    Time frame: From enrollment to the end of treatment at 12 weeks

  5. Heart rate variability

    High Frequency,40%-60%

    Time frame: From enrollment to the end of treatment at 12 weeks

  6. Heart rate variability

    LF/HF,0.6-2.5

    Time frame: From enrollment to the end of treatment at 12 weeks

  7. Heart rate variability

    Heart rate variability ,25ms-70ms

    Time frame: From enrollment to the end of treatment at 12 weeks

  8. Quality of Life(The short version of the World Health Organization Quality of Life ,WHOQOL-BREF)

    WHOQOL-BREF 4 domains,and each one score is 4 - 20. more score more better

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

2 of 2 sites recruiting
  • Renhe nursing home
    New Taipei City, Taiwan
    Recruiting
  • Fuxi nursing home
    Taipei, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Apr 2025, 4 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 4 months is below that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2025
First posted
Mar 17, 2025
StartActual
Dec 2, 2024
Primary completionEst.
Apr 7, 2025
CompletionEst.
Apr 7, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06879925
Lead sponsor
POCHIWU
Responsible party
POCHIWU (nurse、master's candidate, National Taipei University of Nursing and Health Sciences) — Sponsor-investigator
First posted
Mar 17, 2025
Start date
Dec 2, 2024
Primary completion
Apr 7, 2025 (estimated)
Completion
Apr 7, 2025 (estimated)
Last update
Mar 17, 2025

Study contacts

Po-Chi Wu
Contact
mei.lin.w27@gmail.com
+886900622739
Mei-Hua Wang
principal investigator · National Taipei University of Nursing and Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion